Genzyme Takes On Sandoz Over Renagel ANDA

Law360, New York (July 6, 2009, 12:00 AM EDT) -- Genzyme Corp. has targeted Sandoz Inc, the generics arm of Novartis AG, in its latest effort to keep a generic version of Renagel off the market before the expiration of its patent for the well-known kidney treatment.

The Cambridge, Mass.-based drugmaker filed suit Thursday in the U.S. District Court for the District of Maryland over U.S. Patent Number 5,667,775, which covers both Renagel and Renvela, a second-generation form of the drug.

Renagel and Renvela are nonabsorbed, calcium-free, metal-free phosphate binders used to control serum phosphorus in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.